Sacituzumab Govitecan-hziy is named as a drug or biological intervention in 15 clinical trials in our USA, UK, China and Ireland trial registers, 4 of which are recruiting. Lead sponsors include Gilead Sciences (13), Avenzo Therapeutics, Inc. (1) and Tianjin Medical University Second Hospital (1). Registered phases: Phase 3, Phase 2 and Phase 1/2. Conditions studied include Triple Negative Breast Cancer; Non-small Cell Lung Cancer; Endometrial Cancer.
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| Triple Negative Breast Cancer | 4 |
| Non-small Cell Lung Cancer | 1 |
| Endometrial Cancer | 1 |
| Lung Cancer | 1 |
| Advanced or Metastatic Non-Small-Cell Lung Cancer | 1 |
| Resectable Non-Small-Cell Lung Cancer | 1 |
| PD-L1 Positive | 1 |
| Metastatic Urothelial Cancer | 1 |
| Locally Advanced or Unresectable Metastatic Breast Cancer | 1 |
| Stage IV Breast Cancer | 1 |
| PD-L1 Negative | 1 |
| Non-Small Cell Lung Cancer | 1 |
| Metastatic Solid Tumor | 1 |
| Advanced Solid Tumor | 1 |
| HR+/HER2- Breast Cancer | 1 |
| HR+, HER2-, Advanced Breast Cancer | 1 |
| CCNE1 Amplification | 1 |
| Solid Tumor | 1 |
| Precision Medicine | 1 |
| Metastatic Breast Cancer | 1 |
| Metastatic Triple-negative Breast Cancer | 1 |
| Lead sponsor | Trials |
|---|---|
| Gilead Sciences | 13 |
| Avenzo Therapeutics, Inc. | 1 |
| Tianjin Medical University Second Hospital | 1 |
| Register | Sacituzumab Govitecan-hziy trials |
|---|---|
| Clinical trials in USA | 12 |
| Clinical trials in UK | 9 |
| Clinical trials in China | 6 |
| Clinical trials in Ireland | 1 |
A trial with sites in more than one country appears in each of those registers.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Sacituzumab Govitecan-hziy works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Sacituzumab Govitecan-hziy (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 24 Sep 2026.